Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xiaflex: Completed Phase III enrollment

AUXL completed enrollment of a total of >300 patients with at least 20

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE